What youll learn: Both Noom and LifeMD provide access to GLP-1 weight loss medications, but they take different approaches
04, 2026 (GLOBE NEWSWIRE) -- Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Noom's leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer
The SURPASS clinical trial program showed mean heart rate increases of approximately 2 to 4 beats per minute
Temperature stability directly affects your dosing outcomes
Their dual effects on weight and alcohol consumption highlight the shared biology underlying metabolic and addictive disorders
The appetite suppression timeline differs between individuals based on genetics, metabolic rate, and yes, sublingual technique quality